Alexandra Goll
Director/Board Member at Cerenis Therapeutics, Inc.
Profile
Ms. Alexandra Goll is General Partner at TVM Capital GmbH which she joined in 1998.
She is also Mitglied des Vorstands at Addex Pharmaceuticals SA. She is on the Board of Directors at Biovertis AG, Arrow Therapeutics Ltd., Cerenis Therapeutics Holding SA, and Albireo AB.
Dr. Goll also served on the board at Pharmasset, Inc.
Prior to her affiliation with TVM, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd.
in Basel.
She had been involved in clinical development and managing commercialisation strategies of several products.
Dr. Alexandra Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg.
Alexandra Goll active positions
| Companies | Position | Start |
|---|---|---|
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Private Equity Investor | 1997-12-31 |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Director/Board Member | - |
Cerenis Therapeutics, Inc.
 Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI. | Director/Board Member | 2011-11-21 |
Former positions of Alexandra Goll
| Companies | Position | End |
|---|---|---|
| HEIDELBERG PHARMA AG | Director/Board Member | 2011-12-13 |
| ADDEX THERAPEUTICS LTD | Corporate Officer/Principal | 2008-04-16 |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Director/Board Member | 2007-11-01 |
| IDENIX PHARMACEUTICALS INC | Director/Board Member | 2003-04-30 |
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Corporate Officer/Principal | - |
Training of Alexandra Goll
| Freie Universität Berlin | Undergraduate Degree |
| Philipps University of Marburg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ADDEX THERAPEUTICS LTD | Health Technology |
| ABIONYX PHARMA | Health Technology |
| HEIDELBERG PHARMA AG | Health Technology |
| Private companies | 9 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
Biovertis AG
Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Health Technology |
Arrow Therapeutics Ltd.
 Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Cerenis Therapeutics, Inc.
Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Roche Ltd.
Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Finance |
- Stock Market
- Insiders
- Alexandra Goll
